NO139439C - Analogifremgangsmaate til fremstilling av terapeutisk aktive pyrazolon-(5)-forbindelser - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk aktive pyrazolon-(5)-forbindelser

Info

Publication number
NO139439C
NO139439C NO741364A NO741364A NO139439C NO 139439 C NO139439 C NO 139439C NO 741364 A NO741364 A NO 741364A NO 741364 A NO741364 A NO 741364A NO 139439 C NO139439 C NO 139439C
Authority
NO
Norway
Prior art keywords
pyrazolone
compounds
preparation
therapeutic active
analogical procedure
Prior art date
Application number
NO741364A
Other languages
English (en)
Norwegian (no)
Other versions
NO741364L (no
NO139439B (no
Inventor
Eike Moeller
Karl Meng
Egbert Wehinger
Harald Horstmann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2319279A external-priority patent/DE2319279A1/de
Priority claimed from DE2363138A external-priority patent/DE2363138A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO741364L publication Critical patent/NO741364L/no
Publication of NO139439B publication Critical patent/NO139439B/no
Publication of NO139439C publication Critical patent/NO139439C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO741364A 1973-04-17 1974-04-16 Analogifremgangsmaate til fremstilling av terapeutisk aktive pyrazolon-(5)-forbindelser NO139439C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2319279A DE2319279A1 (de) 1973-04-17 1973-04-17 Pyrazolone-(5), verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2363138A DE2363138A1 (de) 1973-12-19 1973-12-19 Pyrazolone-(5), verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
NO741364L NO741364L (no) 1974-10-18
NO139439B NO139439B (no) 1978-12-04
NO139439C true NO139439C (no) 1979-03-14

Family

ID=25764995

Family Applications (1)

Application Number Title Priority Date Filing Date
NO741364A NO139439C (no) 1973-04-17 1974-04-16 Analogifremgangsmaate til fremstilling av terapeutisk aktive pyrazolon-(5)-forbindelser

Country Status (21)

Country Link
US (1) US3952008A (fr)
JP (1) JPS59512B2 (fr)
AR (2) AR207445A1 (fr)
BG (2) BG22394A3 (fr)
CA (1) CA1048513A (fr)
CH (2) CH603593A5 (fr)
DD (1) DD113230A5 (fr)
DK (1) DK136155C (fr)
ES (2) ES425374A1 (fr)
FR (1) FR2226171B1 (fr)
GB (1) GB1424492A (fr)
HK (1) HK55876A (fr)
HU (1) HU168591B (fr)
IE (1) IE39213B1 (fr)
IL (1) IL44627A (fr)
LU (1) LU69871A1 (fr)
NL (1) NL7405116A (fr)
NO (1) NO139439C (fr)
PL (1) PL96880B1 (fr)
RO (2) RO63750A (fr)
SE (1) SE408552B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319278C2 (de) * 1973-04-17 1986-02-20 Bayer Ag, 5090 Leverkusen Pharmazeutisches Mittel
USRE30420E (en) * 1973-04-17 1980-10-21 Bayer Aktiengesellschaft Pyrazol-5-ones
US4056533A (en) * 1973-04-17 1977-11-01 Bayer Aktiengesellschaft Pyrazol-5-ones
US4000294A (en) * 1973-04-17 1976-12-28 Bayer Aktiengesellschaft Pyrazol-5-ones
DE2427272C3 (de) * 1974-06-06 1981-10-01 Bayer Ag, 5090 Leverkusen 1-(2-(β-Naphthyloxy)-äthyl)-3-methyl -pyrazolon-(5), Verfahren sowie Verwendung als Antithrombotikum
DE2526469A1 (de) * 1975-06-13 1976-12-30 Bayer Ag 1-substituierte pyrazolderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS5585571A (en) * 1978-12-22 1980-06-27 Nippon Synthetic Chem Ind Co Ltd:The Preparation of 1,3-disubstituted-5-pyrazolone
JPH0730031B2 (ja) * 1986-04-02 1995-04-05 日産化学工業株式会社 ２―ピラゾリン―５―オン類の製造法
WO2006094201A2 (fr) * 2005-03-02 2006-09-08 La Jolla Pharmaceutical Company Inhibiteurs de l'amine oxydase sensible aux semicarbazides (ssao) et adhesion induite par vap-1 utilisee pour le traitement de maladies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2376380A (en) * 1945-05-22 Preparation of amino pyrazolones
GB636988A (en) * 1947-12-24 1950-05-10 Gevaert Photo Producten Naamlo Improvements in and relating to the production of colour photographic images
US2511231A (en) * 1949-03-26 1950-06-13 Eastman Kodak Co 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography
US2600788A (en) * 1949-06-07 1952-06-17 Eastman Kodak Co Halogen-substituted pyrazolone couplers for color photography
US2672417A (en) * 1949-12-31 1954-03-16 Gevaert Photo Prod Nv Production of color photographic images
NL121416C (fr) * 1961-05-31

Also Published As

Publication number Publication date
CA1048513A (fr) 1979-02-13
ES425374A1 (es) 1976-09-16
DK136155C (da) 1978-01-30
IE39213B1 (en) 1978-08-30
CH603593A5 (fr) 1978-08-31
AR207242A1 (es) 1976-09-22
IL44627A0 (en) 1974-06-30
FR2226171A1 (fr) 1974-11-15
HK55876A (en) 1976-09-17
BG22394A3 (bg) 1977-02-20
FR2226171B1 (fr) 1978-07-28
RO69408A (fr) 1980-06-15
JPS5012082A (fr) 1975-02-07
RO63750A (fr) 1980-06-15
DK136155B (da) 1977-08-22
JPS59512B2 (ja) 1984-01-07
ES447081A1 (es) 1977-06-16
BG22820A3 (bg) 1977-04-20
IE39213L (en) 1974-10-17
US3952008A (en) 1976-04-20
NO741364L (no) 1974-10-18
DD113230A5 (fr) 1975-05-20
LU69871A1 (fr) 1974-11-21
GB1424492A (en) 1976-02-11
NO139439B (no) 1978-12-04
NL7405116A (fr) 1974-10-21
CH605799A5 (fr) 1978-10-13
IL44627A (en) 1978-07-31
HU168591B (fr) 1976-06-28
AU6817574A (en) 1975-10-23
AR207445A1 (es) 1976-10-08
PL96880B1 (pl) 1978-01-31
SE408552B (sv) 1979-06-18

Similar Documents

Publication Publication Date Title
NO138805C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive triazolforbindelser
NO140854C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptid-amider
NO145382C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-amino-indazolkarboksylsyrederivater.
NO140300C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (omega-1)-oksodialkylxantiner
NO137092C (no) Analogifremgangsm}te til fremstilling av anthelmintisk virksomme 2-karbalkoksyamino-benzimidazol-5(6)-fenyletere
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
NO149281C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 7alfa-metoksycephalosporinderivater
NO145056C (no) (s)-1-aryloksy-2-propanolderivater for fremstilling av terapeutisk aktive (s)-1-aryloksy-3-amino-2-propanolderivater
NO140597C (no) Analogifremgangsmaate ved fremstillingen av terapeutisk aktive 8-azapurin-6-on-derivater
NO139685C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoindolin-derivater
NO740606L (no) Analogifremgangsmåte til fremstilling av terapeutisk virksomme 3-klor-7-alfa-amino-acylcefalosporinforbindelser.
NO138530C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1-substituerte pyrazolon-(5)-derivater
NO140978C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater
NO139439C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive pyrazolon-(5)-forbindelser
NO137387C (no) Analogifremgangsm}te til fremstilling av 5-metyltiopyrimidiner med terapeutisk virkning
NO143064C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive hydroksyalkylxantiner
NO137550C (no) Analogifremgangsmaate til fremstilling av anti-inflammatorisk virksomme 2,4,5-trisubstituerte oksazolforbindelser
NO136408C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive 2-fenylaminoimidazolin (2)-forbindelser
SE409716B (sv) Analogiforfarande for framstellning av 11beta-alkyl-deltaŸ4-estrener
NO141208C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 2-(fenoksyalkyltio)imidazolforbindelser
NO144110C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 5:6-benzo-4-pyron-derivater
NO145383C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte indoler.
NO138025C (no) Analogifremgangsmaate til fremstilling av antimykotisk virksomme 1-etyl-imidazoler
SE421693B (sv) Forfarande for framstellning av n-substituerade 1-amino-3-fenoxi-propanoler-(2)
NO143499C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indanderivater